Key Points
- Insider sale: Aimee Lenar sold 36,827 Bausch Health shares at an average price of $7.03, totaling approximately $258,894. The transaction, conducted under a Rule 10b5-1 plan, reduced her holdings by 9.91% to 334,853 shares.
- Quarterly results: Bausch Health reported quarterly earnings of $1.26 per share, beating analyst estimates of $0.96, while revenue of $2.83 billion exceeded expectations of $2.59 billion.
- Analyst sentiment remains cautious: The stock has an average “Reduce” rating, with five Hold ratings and two Sell ratings, and a consensus price target of $8.00. Shares opened at $6.84 and have traded between $4.33 and $8.00 over the past year.
Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) insider Aimee Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider directly owned 334,853 shares of the company's stock, valued at approximately $2,354,016.59. This represents a 9.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bausch Health Cos Stock Performance
NYSE BHC opened at $6.84 on Friday. The business's 50-day moving average price is $5.33 and its 200 day moving average price is $5.46. Bausch Health Cos Inc. has a twelve month low of $4.33 and a twelve month high of $8.00. The company has a market capitalization of $2.56 billion, a PE ratio of -2.31 and a beta of 0.38. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68.
Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.30. The firm had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. On average, research analysts predict that Bausch Health Cos Inc. will post 4.35 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada lowered their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a "sector perform" rating for the company in a report on Monday, April 27th. Weiss Ratings raised shares of Bausch Health Cos from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday, July 31st. Jefferies Financial Group upgraded Bausch Health Cos to a "hold" rating in a report on Wednesday, July 22nd. Zacks Research lowered Bausch Health Cos from a "hold" rating to a "strong sell" rating in a research report on Friday, July 24th. Finally, Wall Street Zen upgraded Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 1st. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus target price of $8.00.
View Our Latest Analysis on BHC
Hedge Funds Weigh In On Bausch Health Cos
A number of hedge funds have recently made changes to their positions in BHC. Tacita Capital Inc acquired a new stake in Bausch Health Cos in the 2nd quarter valued at $29,000. Caption Management LLC lifted its stake in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company's stock worth $31,000 after purchasing an additional 405,789 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company's stock worth $34,000 after buying an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company's stock worth $35,000 after buying an additional 5,329 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock valued at $51,000 after buying an additional 3,106 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.
About Bausch Health Cos
(
Get Free Report)
Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.
The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
